Bexarotene: Cutaneous lymphoma: Too many adverse effects

Prescrire International

Volumn 13, Issue 71, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CYTOCHROME P450 3A4; GEMFIBROZIL; IMIDAZOLE; LIPID; MACROLIDE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RETINOID DERIVATIVE; STEROID; THYROID HORMONE; ANTINEOPLASTIC AGENT; TETRALIN DERIVATIVE;

ANEMIA; ARTICLE; BEAM THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CATARACT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG WITHDRAWAL; DRY SKIN; ESTHETICS; EXFOLIATIVE DERMATITIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; MEDICAL PHOTOGRAPHY; METHODOLOGY; NAUSEA AND VOMITING; NONHUMAN; PANCREATITIS; PERIPHERAL EDEMA; PRESCRIPTION; PUVA; QUALITY OF LIFE; RAT; RISK ASSESSMENT; SKIN LYMPHOMA; T CELL LYMPHOMA; TERATOGENICITY; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; CUTANEOUS T CELL LYMPHOMA; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; TETRAHYDRONAPHTHALENES;

EID: 3142692817     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Prescrire Rédaction "Les lymphomes non hodgkiniens" Rev Prescrire 2003; 23 (237): 209-214.
2. The European Agency for the Evaluation of Medicinal Products "European Public Assessment Report - Targretin (bexarotene)" 27 June 2001: 58 pages.
3. Food and Drug Administration - Center for Drug Evaluation and Research "NDA21055 medical review" 23 December 1999: 120 pages.
4. Siegel RS et al. "Primary cutaneous T-cell lymphoma: review and current concepts" J Clin Oncol 2000; 18: 2908-2925.
5. Muche JM et al. "Treatment of cutaneous T-cell lymphomas" Semin Cut Med Surg 2000; 19 (2): 142-148.
6. Apisarnthanarax N et al. "Treatment of cutaneous T cell lymphoma" Am J Clin Dermatol 2002; 3 (3): 193-215.
7. o: encore bien des incertitudes" Rev Prescrire 1999; 19 (193): 180-183.
8. Duvic M et al. "Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma" Arch Dermatol 2001; 137: 581-593.
9. Duvic M et al. "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results" J Clin Oncol 2001; 19: 2456-2471.
10. Food and Drug Administration - Center for Drug Evaluation and Research "Clinical team leader supplement to medical officer review of NDA 21055" 23 December 1999: 22 pages.
11. Elan "Targretin - Monographie": 48 pages.
12. Talpur R et al. "Optimizing bexarotene therapy for cutaneous T-cell lymphoma" J Am Acad Dermatol 2002; 47: 672-684.